Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination

Journal of Infectious Diseases

Volumn 196, Issue 6, 2007, Pages 861-867

  Jokinen, Sari ^a   Österlund, Pamela ^a   Julkunen, Ilkka ^a   Davidkin, Irja ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; MEASLES MUMPS RUBELLA VACCINE;

ADULT; ANTIBODY DETECTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; MUMPS VIRUS; PRIORITY JOURNAL; RUBELLA; VACCINATION;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS;

EID: 34548480924     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/521029     Document Type: Article

References (30)

1. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-402.
2. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 2000; 284:2643-7.
3. Plotkin SA, Wharton M. Mumps vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB. Saunders, 1999:267-92.
4. Leinikki P. Mumps. In: Zuckerman A, Banatvala J, Pattison J, Griffiths P, Schoub B, eds. Principles and practice of clinical virology. 5th ed. Chichester, UK: John Wiley & Sons, 2004:459-66.
5. Nokes D, Anderson R. Measles, mumps and rubella vaccine: what coverage to block transmission? Lancet 1988; 2:1374.
6. Centers for Disease Control and Prevention. Update: multistate outbreak of mumps - United States, January 1-May 2, 2006. MMWR 2006; 55:559-63.
7. Gut J-P, Lablache C, Behr S, Kirn A. Symptomatic mumps virus reinfections. J Med Virol 1995; 45:17-23.
8. Crowley B, Afzal M. Mumps virus reinfection - clinical findings and serological vagaries. Commun Dis Public Health 2002; 5:311-3.
9. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005; 191:719-23.
10. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination: a nine-year follow-up. Vaccine 1995; 13:1617-22.
11. Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999; 150:1238-49.
12. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26.
13. Good RA, Zak SJ. Disturbances in gamma globulin synthesis as "experiments of nature." Pediatrics 1956; 18:109-49.
14. Dhiman N, Ovsyannikova IG, Jacobson RM, et al. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin Immunol 2005; 115:154-61.
15. Broliden K, Abreu ER, Arneborn M, Bottiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16:323-7.
16. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996; 15:687-92.
17. Nakayama T, Urano T, Osano M, et al. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Microbiol Immunol 1990; 34:497-508.
18. Peltola H, Karanko V, Kurki T, et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986; 1:137-9.
19. Julkunen I, Hautanen A, Keski-Oja J. Interaction of viral envelope glycoproteins with fibronectin. Infect Immun 1983; 40:876-81.
20. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999; 162:5569-75.
21. Ding Y, Fu S, Zamarin D, Bromberg J. Interleukin-10. In: Thomson AW, Lotze MT, eds. The cytokine handbook. Vol 1. 4th ed. London: Academic Press, 2003:603-25.
22. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18:42-8.
23. Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. Pediatr Infect Dis J 2005; 24:1083-8.
24. Cruz Rojo C, Rodríguez Iglesias M, Olvera J, Álvarez Girón M. Study of the immune response engendered by different combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003; 22:280-6.
25. Christenson B, Bottiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals 1990; 18:213-9.
26. Backhouse J, Gidding H, McIntyre P, Gilbert G. Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus. Clin Vaccine Immunol 2006; 13:764-7.
27. Mossong J, Muller CP. Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine 2003; 21: 4597-603.
28. Glass K, Grenfell BT. Antibody dynamics in childhood diseases: waning and boosting of immunity and the impact of vaccination. J Theor Biol 2003; 221:121-31.
29. Kancherla VS, Hanson IC. Mumps resurgence in the United States. J Allergy Clin Immunol 2006; 118:938-41.
30. Weibel R, Stokes J Jr, Buynak E, Whitman J Jr, Hilleman M. Live, attenuated mumps-virus vaccine 3: clinical and serologic aspects in a field evaluation. N Engl J Med 1967; 276:245-51.